The effect of cyclophosphamide on immunological memory.

Area of Science:

• Immunology
• Pharmacology

Background:

• Intradermal injection of bovine gammaglobulin (BGG) anti-BGG immune complexes induces delayed hypersensitivity and immune priming.
• This priming is detectable via antihapten and anticarrier humoral immune responses.
• Cyclophosphamide (CY) is an immunosuppressive drug with potential selective effects on immune responses.

Purpose of the Study:

• To investigate the selective effects of cyclophosphamide (CY) on antihapten and anticarrier immune responses.
• To determine how CY administration timing and dosage influence IgG1 and IgG2 antibody production.
• To explore the differential susceptibility of memory and effector cells to CY.

Main Methods:

• Induction of delayed hypersensitivity and immune priming using BGG-anti-BGG complexes in adjuvant.
• Administration of cyclophosphamide (CY) as multiple small doses or a single large dose at various time points post-sensitization.
• Measurement of antihapten (anti-DNP) and anticarrier (anti-BGG) IgG1 and IgG2 antibody responses.

Main Results:

• Multiple CY doses suppressed antihapten IgG2 but not IgG1 priming, suggesting selective inhibition of IgG2 suppressor cells.
• A large single CY dose enhanced IgG2 production while not affecting IgG1, further supporting selective targeting of suppressor cells.
• CY administration on day +3 impaired both IgG1 and IgG2 responses, while days 0 and +7 showed different effects, indicating distinct memory cell susceptibilities.

Conclusions:

• Cyclophosphamide exhibits selective effects on the development of antihapten and anticarrier antibody responses.
• The differential impact of CY suggests distinct regulatory mechanisms and susceptibilities for IgG1 and IgG2 antibody production.
• Memory cells involved in IgG1 and IgG2 responses, as well as effector cells in delayed hypersensitivity, show varying sensitivities to cyclophosphamide.